MA51625B1 - Procédé de production de modulateurs de somatostatine - Google Patents
Procédé de production de modulateurs de somatostatineInfo
- Publication number
- MA51625B1 MA51625B1 MA51625A MA51625A MA51625B1 MA 51625 B1 MA51625 B1 MA 51625B1 MA 51625 A MA51625 A MA 51625A MA 51625 A MA51625 A MA 51625A MA 51625 B1 MA51625 B1 MA 51625B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- modulators
- somatostatin modulators
- producing somatostatin
- producing
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title abstract 3
- 108010056088 Somatostatin Proteins 0.000 title abstract 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 3
- 229960000553 somatostatin Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Optical Communication System (AREA)
- Eye Examination Apparatus (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des composés qui sont des modulateurs de la somatostatine, des procédés de production desdits composés, des compositions pharmaceutiques et des médicaments comprenant lesdits composés, ainsi que des procédés d'utilisation de ces composés dans le traitement d'états pathologiques, de maladies ou de troubles qui peuvent tirer avantage de la modulation de l'activité de la somatostatine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618538P | 2018-01-17 | 2018-01-17 | |
| PCT/US2019/013844 WO2019143718A1 (fr) | 2018-01-17 | 2019-01-16 | Procédé de production de modulateurs de somatostatine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51625A MA51625A (fr) | 2021-04-21 |
| MA51625B1 true MA51625B1 (fr) | 2022-07-29 |
Family
ID=67213594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51625A MA51625B1 (fr) | 2018-01-17 | 2019-01-16 | Procédé de production de modulateurs de somatostatine |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10464918B2 (fr) |
| EP (2) | EP4092018A1 (fr) |
| JP (2) | JP7113900B2 (fr) |
| KR (1) | KR102462586B1 (fr) |
| CN (1) | CN111868049B (fr) |
| AU (1) | AU2019209469B2 (fr) |
| CA (1) | CA3088658A1 (fr) |
| CY (1) | CY1125354T1 (fr) |
| DK (1) | DK3740475T3 (fr) |
| EA (1) | EA202091559A1 (fr) |
| ES (1) | ES2923529T3 (fr) |
| HR (1) | HRP20220852T1 (fr) |
| HU (1) | HUE059184T2 (fr) |
| IL (1) | IL276029B2 (fr) |
| LT (1) | LT3740475T (fr) |
| MA (1) | MA51625B1 (fr) |
| MD (1) | MD3740475T2 (fr) |
| MX (1) | MX2020007586A (fr) |
| PL (1) | PL3740475T3 (fr) |
| PT (1) | PT3740475T (fr) |
| RS (1) | RS63387B1 (fr) |
| SG (1) | SG11202006838VA (fr) |
| SI (1) | SI3740475T1 (fr) |
| SM (1) | SMT202200298T1 (fr) |
| TW (1) | TWI823891B (fr) |
| UA (1) | UA127355C2 (fr) |
| WO (1) | WO2019143718A1 (fr) |
| ZA (1) | ZA202004497B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264178B2 (en) | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| EP3658560A4 (fr) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | Modulateurs de la somatostatine et utilisations de ces derniers |
| PT3740475T (pt) | 2018-01-17 | 2022-07-18 | Crinetics Pharmaceuticals Inc | Processo de produção de moduladores da somatostatina |
| CA3191084A1 (fr) * | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations d'un modulateur de somatostatine |
| CN113214050B (zh) * | 2021-05-15 | 2022-07-19 | 宁夏忠同生物科技有限公司 | 一种合成2,3,5,6-四氟苯酚的方法 |
| BR112023024465A2 (pt) * | 2021-05-25 | 2024-02-06 | Crinetics Pharmaceuticals Inc | Usos de um modulador de somatostatina para o tratamento de doença |
| WO2023137018A1 (fr) * | 2022-01-11 | 2023-07-20 | Crinetics Pharmaceuticals, Inc. | Utilisations d'un modulateur de somatostatine pour le traitement du syndrome carcinoïde |
| EP4547654A1 (fr) | 2022-06-10 | 2025-05-07 | Assia Chemical Industries Ltd. | Formes à l'état solide de paltusotine et leur procédé de préparation |
| KR20250162795A (ko) | 2023-03-28 | 2025-11-19 | 크리네틱스 파마슈티칼스, 인크. | 간 기능장애가 있는 환자에게 팔투소틴을 투여하기 위한 조성물 및 방법 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1035154A (en) | 1910-05-16 | 1912-08-13 | Ernest G Clark | Machine for rectifying perforated music and masters. |
| US1046491A (en) | 1910-08-24 | 1912-12-10 | Alfred Randolph | Gas-engine. |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| CA2468159A1 (fr) * | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | Composes 4-aminoquinoleines |
| WO2003066055A1 (fr) * | 2002-02-04 | 2003-08-14 | F. Hoffmann-La Roche Ag | Derives de quinoline (n) en tant qu'antagonistes du neuropeptide y (npy) |
| US7767817B2 (en) | 2003-09-05 | 2010-08-03 | Binghe Wang | Water soluble boronic acid fluorescent reporter compounds and methods of use thereof |
| JP2008506695A (ja) | 2004-07-13 | 2008-03-06 | グラクソ グループ リミテッド | 抗細菌剤 |
| AU2007309708A1 (en) * | 2006-03-13 | 2008-05-02 | Merck Sharp & Dohme Corp. | Somatostatin agonists |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| CA2806332C (fr) | 2010-07-30 | 2017-11-14 | Oncotherapy Science, Inc. | Derives de quinoline et inhibiteurs de melk les contenant |
| RU2637936C2 (ru) * | 2011-05-23 | 2017-12-08 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
| US20140228417A1 (en) * | 2011-10-05 | 2014-08-14 | Mapi Pharma Ltd. | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
| WO2014007228A1 (fr) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| US9643951B2 (en) * | 2013-09-30 | 2017-05-09 | Ono Pharmaceutical Co., Ltd. | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| WO2016049568A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Méthodes et compositions permettant l'inhibition de la ras |
| EP3317278B1 (fr) * | 2015-07-01 | 2021-04-14 | Crinetics Pharmaceuticals, Inc. | Modulateurs de somatostatine et leurs utilisations |
| US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| IL264178B2 (en) | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| PT3740475T (pt) | 2018-01-17 | 2022-07-18 | Crinetics Pharmaceuticals Inc | Processo de produção de moduladores da somatostatina |
-
2019
- 2019-01-16 PT PT197407331T patent/PT3740475T/pt unknown
- 2019-01-16 WO PCT/US2019/013844 patent/WO2019143718A1/fr not_active Ceased
- 2019-01-16 PL PL19740733.1T patent/PL3740475T3/pl unknown
- 2019-01-16 MA MA51625A patent/MA51625B1/fr unknown
- 2019-01-16 SI SI201930277T patent/SI3740475T1/sl unknown
- 2019-01-16 MD MDE20201200T patent/MD3740475T2/ro not_active IP Right Cessation
- 2019-01-16 SM SM20220298T patent/SMT202200298T1/it unknown
- 2019-01-16 JP JP2020538675A patent/JP7113900B2/ja active Active
- 2019-01-16 ES ES19740733T patent/ES2923529T3/es active Active
- 2019-01-16 SG SG11202006838VA patent/SG11202006838VA/en unknown
- 2019-01-16 HU HUE19740733A patent/HUE059184T2/hu unknown
- 2019-01-16 MX MX2020007586A patent/MX2020007586A/es unknown
- 2019-01-16 UA UAA202004625A patent/UA127355C2/uk unknown
- 2019-01-16 CA CA3088658A patent/CA3088658A1/fr active Pending
- 2019-01-16 DK DK19740733.1T patent/DK3740475T3/da active
- 2019-01-16 AU AU2019209469A patent/AU2019209469B2/en active Active
- 2019-01-16 US US16/249,729 patent/US10464918B2/en active Active
- 2019-01-16 HR HRP20220852TT patent/HRP20220852T1/hr unknown
- 2019-01-16 EP EP22168295.8A patent/EP4092018A1/fr not_active Withdrawn
- 2019-01-16 KR KR1020207023546A patent/KR102462586B1/ko active Active
- 2019-01-16 RS RS20220660A patent/RS63387B1/sr unknown
- 2019-01-16 CN CN201980019970.7A patent/CN111868049B/zh active Active
- 2019-01-16 IL IL276029A patent/IL276029B2/en unknown
- 2019-01-16 EA EA202091559A patent/EA202091559A1/ru unknown
- 2019-01-16 EP EP19740733.1A patent/EP3740475B1/fr active Active
- 2019-01-16 LT LTEPPCT/US2019/013844T patent/LT3740475T/lt unknown
- 2019-01-17 TW TW108101800A patent/TWI823891B/zh active
- 2019-10-03 US US16/592,595 patent/US10889561B2/en active Active
-
2020
- 2020-07-21 ZA ZA2020/04497A patent/ZA202004497B/en unknown
- 2020-12-09 US US17/116,728 patent/US20210087165A1/en not_active Abandoned
-
2022
- 2022-07-12 CY CY20221100472T patent/CY1125354T1/el unknown
- 2022-07-26 JP JP2022118926A patent/JP2022166016A/ja active Pending
-
2024
- 2024-02-26 US US18/587,187 patent/US20240376067A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51625B1 (fr) | Procédé de production de modulateurs de somatostatine | |
| MA58049B1 (fr) | Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations | |
| BR112022002683A2 (pt) | Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA53665B1 (fr) | Agonistes du récepteur farnésoïde x et leurs utilisations | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA53861B1 (fr) | Modulateurs de promédicaments de la voie de réponse intégrée au stress | |
| MA46018A (fr) | Activateurs d'édition du génome | |
| MA47043A1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
| MA54231A (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
| WO2018112446A3 (fr) | Utilisation de gènes à médiation par motif apoe4 pour le diagnostic et le traitement de la maladie d'alzheimer | |
| MA47392A1 (fr) | Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques | |
| MA30462B1 (fr) | Composes de pyridylamide antagonistes des canaux calciques de type t | |
| Post et al. | Developmental psychobiology of cyclic affective illness: Implications for early therapeutic intervention | |
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| WO2019236775A8 (fr) | Agents actifs et leurs procédés d'utilisation pour le traitement de troubles métaboliques et d'une stéatose hépatique non alcoolique | |
| MA28660B1 (fr) | Composes et compositions en tant que modulateurs de ppar | |
| MA49947B1 (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
| MA67288A1 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| EP4548974A3 (fr) | Modulateurs de somatostatine et leurs utilisations | |
| EP4603142A3 (fr) | Antagonistes du récepteur du sous-type 2 de la mélanocortine à base de pipéridine spirocyclique (mc2r) et leurs utilisations | |
| TR200201094T2 (tr) | Farmasötik maddeler olarak bisiklik amino asitler | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| EP3934646A4 (fr) | Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires | |
| MA30720B1 (fr) | Analogues de 2-phenoxypyrimidinone |